Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

1165

10.17650/1726-9776-2006-2-3-30-33

DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCER

ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыря

Management of patients with urinary bladder cancer at T1G3 stage

Лечение больных раком мочевого пузыря в стадии Т1G3

Panakhov

A. D.

Панахов

А. Д.

Russian Federation

Москва

Figurin

K. M.

Фигурин

К. М.

Russian Federation

Москва

Kamolov

B. Sh.

Камолов

Б. Ш.

Russian Federation

Москва

Seregin

I. V.

Серегин

И. В.

Russian Federation

Москва

Sokolova

I. N.

Соколова

И. Н.

Russian Federation

Москва

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМН

30092006

30331802202018022020

https://oncourology.abvpress.ru/oncur/article/view/1165

1. Herr H.W., Jakse G., Sheinfeld J. The T1 bladder tumor. Semin Urol 1990; 8: 254.

Herr H.W., Jakse G., Sheinfeld J. The T1 bladder tumor. Semin Urol 1990; 8: 254.

2. Holmang S., Hedelin H., Anderstrom C. et al. The importance of the depth of invasion in stage T1 bladder carcinoma: A prospective cohort study. J Urol 1997; 157: 800.

Holmang S., Hedelin H., Anderstrom C. et al. The importance of the depth of invasion in stage T1 bladder carcinoma: A prospective cohort study. J Urol 1997; 157: 800.

3. Hurle R., Losa A., Ranieri A. et al. Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258–63.

Hurle R., Losa A., Ranieri A. et al. Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258–63.

4. Cheng L., Weaver A.L., Neumann R.M. et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999; 86: 1035.

Cheng L., Weaver A.L., Neumann R.M. et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999; 86: 1035.

5. Shahin O., Thalmann G.N., Rentsch C. et al. A retrospective analysis of 153 patients treated with or without intravesical BCG for primary stage T1 grade G3 bladder cancer: recurrence, progression, survival. J Urol 2003; 169: 96–100.

Shahin O., Thalmann G.N., Rentsch C. et al. A retrospective analysis of 153 patients treated with or without intravesical BCG for primary stage T1 grade G3 bladder cancer: recurrence, progression, survival. J Urol 2003; 169: 96–100.

6. Heney N.M., Ahmed S., Flanagan M.J. et al. National Bladder Cancer Collaborative Group A: Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083.

Heney N.M., Ahmed S., Flanagan M.J. et al. National Bladder Cancer Collaborative Group A: Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083.

7. Jakse G., Loidl W., Seeber G., Hofstadter F. Stage T1, grade 3 transitional carcinoma of the bladder: an unfavourable tumour. J Urol 1984;137:39–43.

Jakse G., Loidl W., Seeber G., Hofstadter F. Stage T1, grade 3 transitional carcinoma of the bladder: an unfavourable tumour. J Urol 1984;137:39–43.

8. Kaubisch S., Lum B.L., Reese J. et al. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991; 146: 28–31.

Kaubisch S., Lum B.L., Reese J. et al. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991; 146: 28–31.

9. Lutzeyer W., Rübben H., Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127: 250–2.

Lutzeyer W., Rübben H., Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127: 250–2.

10.

10. Baniel J., Grauss D., Engelstein D. et al. Intravesical bacillus treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52: 785–9.

Baniel J., Grauss D., Engelstein D. et al. Intravesical bacillus treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52: 785–9.

11.

11. Brake M., Loertzer H., Horsch R. et al. Reccurence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000; 163: 1697–701.

Brake M., Loertzer H., Horsch R. et al. Reccurence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000; 163: 1697–701.

12.

12. Gohji K., Nomi M., Okamoto M. et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999; 53: 308.

Gohji K., Nomi M., Okamoto M. et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999; 53: 308.

13.

13. Klän R., Steiner U., Sauter T. et al: Zystektomie beim schlecht differenzierten T1-Harnblasenkarzinom—oft zu früh? Akt Urol 1998; 29: 53.

Klän R., Steiner U., Sauter T. et al: Zystektomie beim schlecht differenzierten T1-Harnblasenkarzinom—oft zu früh? Akt Urol 1998; 29: 53.

14.

14. Lebret T., Gaudez F., Herve J.M. et al. Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumors: recurrence, progression and success. Eur Urol 1998; 34: 67–72.

Lebret T., Gaudez F., Herve J.M. et al. Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumors: recurrence, progression and success. Eur Urol 1998; 34: 67–72.

15.

15. Pansadoro V., Emiliozzi P., De Paula F. et al. Long-term follow-up of T1G3 Transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 227–31.

Pansadoro V., Emiliozzi P., De Paula F. et al. Long-term follow-up of T1G3 Transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 227–31.

16.

16. Oosterlinck W., Lobel B., Jakse G. et al. The EAU Working group on Oncological Urology. European Association of Urology Guidelines on bladder cancer. Eur Urol 2002; 41: 105–12.

Oosterlinck W., Lobel B., Jakse G. et al. The EAU Working group on Oncological Urology. European Association of Urology Guidelines on bladder cancer. Eur Urol 2002; 41: 105–12.

17.

17. Cookson M.S, Herr H.W., Zhang Z.F. et al. The treated natural history of high risk superficial bladder cancer: 15-year out-come. J Urol 1997; 158: 62–7.

Cookson M.S, Herr H.W., Zhang Z.F. et al. The treated natural history of high risk superficial bladder cancer: 15-year out-come. J Urol 1997; 158: 62–7.